The review found that cognitive behavioural therapy (CBT) appeared to improve coping with pain and reduced depressed mood and healthcare-seeking behaviour in individuals with fibromyalgia. In view of limitations of the review (in particular clinical, methodological and statistical heterogeneity between the studies) these conclusions should be regarded with caution.
Study selection
Eligible randomised controlled trials (RCTs) compared CBT with no treatment, treatment as usual, attention control or active therapy for individuals of any age with fibromyalgia syndrome (diagnosed with recognised criteria). CBT was defined as face-to-face cognitive, operant behavioural or cognitive behavioural therapy with defined psychotherapeutic content as a central part of treatment. Studies were required to assess pain, sleep, fatigue and/or health-related quality of life. Secondary outcomes were depressed mood, pain self-efficacy (coping with pain) and healthcare seeking behaviour. Studies of CBT combined with other treatment were excluded.
The median age of participants was 47 years (range 16 to 54 years). Most were women (88% to 100%) and 86% to 94% were Caucasian. Nearly all studies excluded participants with somatic disease and half excluded those with mental disorders. Participants were recruited from diverse settings (hospital registers, referral by health providers, local selfhelp groups and newspaper advertisements). Studies were conducted in single centres in North America and Europe. Interventions were CBT, cognitive mindfulness-based stress reduction and operant behavioural therapy. Interventions were delivered as group therapy, mostly in out-patient settings, over five to 15 weeks, for a median of 27 hours in total (range six to 75 hours). Median attendance rate was 75% (where reported). Controls received treatment as usual/no therapy, another active therapy (such as aerobic exercise) or attention control (such as education). Primary outcomes varied widely (such as pain, coping with pain and depression, disability, affective distress, physician visits, sleep quality, depressed mood, health-related quality of life, side effects). Most studies included follow up (median six months, range two to 48 months).
Two reviewers independently selected the studies.
Assessment of study quality
The following aspects of study validity were considered: adequacy of randomisation, allocation concealment, blinding of assessment, use of intention-to-treat analysis, and representativeness of the study sample. The quality of the intervention was assessed with a nine point published scale (Yates 2005).
Two pairs of reviewers independently assessed study validity.
Data extraction
For each study, the reviewers selected one measure for each outcome and one control group (prioritised as follows: attention placebo, treatment as usual, active control). Mean differences between the study groups (in end scores or change scores) were calculated. Standard deviations were extracted, calculated or imputed. The direction of
Methods of synthesis
Studies were combined using a random-effects inverse variance model to calculate standardised mean differences (SMDs) between the groups. Heterogeneity was evaluated with Ι² (>50% indicating strong heterogeneity). Τ² was used to assess differences between subgroups. Publication bias was assessed with funnel plots. Subgroup or sensitivity analyses were conducted to examine the effects of type and duration of CBT, type of control, inclusion (or not) of individuals with affective or anxiety disorders, study quality and publication year.
Results of the review
Fourteen RCTs were included (approximately 910 participants in included arms, range 14 to 131). Five were adequately randomised, two had adequate allocation concealment, three used blinded assessment and ten used intention-to-treat. Reported quality of treatment was low in most studies (score range 2-8 out of 9 points). Median follow up (where reported) was six months (range two to 48 months).
At post treatment, CBT significantly reduced depressed mood, with a small effect (SMD -0.24, 95% CI -0.40 to -0.08; 10 RCTs, Ι²=0%) and improved pain self-efficacy with a large effect (SMD 0.85, 95% CI 0.25 to 1.46; eight RCTs, Ι²=89%) compared with controls. CBT had no significant effect on pain (12 RCTs), fatigue (four RCTs), sleep (four RCTs) or health-related quality of life (eight RCTs).
At the latest follow-up, CBT significantly improved self-efficacy pain (SMD 0.90, 95% CI 0.14 to 0.66; seven study arms, Ι²=90%), and operant behavioural therapy significantly decreased physician visits (SMD -1.57, 95% CI -2.00 to -1.14; two arms, Ι²=0%) compared with controls, both with a large effect. CBT had no significant effect on pain (10 arms), fatigue (four arms), sleep (four arms), depressed mood (eight arms), or health-related quality of life (seven arms).
Four RCTs reported side-effects but no comparative statistical data were reported.
There was high statistical heterogeneity for most outcomes (pain, sleep, fatigue, health-related quality of life and selfefficacy pain at both follow-up times). In sensitivity analyses by study quality, the benefit of CBT on depressed mood was not clearly distinguishable from the effects of potential study bias. There was no indication of publication bias.
